Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
AIDS/HIV
99%
Microbicides
66%
Cervicovaginal Lavage
53%
HIV-infected Patients
39%
Herpes Simplex Virus
36%
Vaginal Microbiota
35%
Topical Microbicides
31%
COVID-19
31%
Female Genital Tract
28%
Placebo
27%
Genital Tract
27%
Human Papillomavirus
26%
Mucosal Immunity
26%
Genital Herpes
25%
Herpes Simplex Virus 2 (HSV-2)
25%
Vaginal Ring
24%
Herpes Simplex Virus Infection
23%
Immune Mediators
22%
Vaginal Microbicides
22%
HIV Prevention
21%
Clinical Trials
21%
Escherichia Coli
20%
Antiretroviral Therapy
20%
Bacterial Vaginosis
19%
Tenofovir Disoproxil Fumarate
18%
Cervical Cancer
18%
HIV Infection
17%
Mucosal Immune Response
17%
Virus Activity
17%
Human Immunodeficiency Virus Type 1 (HIV-1)
17%
Vaginal Gel
16%
Antiviral Activity
15%
Randomized Placebo-controlled Trial
15%
Cervical mucus
15%
Tenofovir
15%
Sexually Active
14%
Nonoxynol-9
14%
Pre-exposure Prophylaxis (PrEP)
14%
Pharmacokinetics
14%
New York City
14%
Anti-herpes Simplex Virus
13%
Living with
13%
Murine Model
13%
Human Immunodeficiency Virus Infection
13%
Antimicrobial Activity
13%
Virus
12%
95% Confidence Interval
12%
Translational Science
12%
Papillomavirus Infections
12%
Bronx
11%
Immunology and Microbiology
Human Immunodeficiency Virus
94%
Antimicrobial Agent
54%
Infection
46%
Infectious Disease
45%
Herpes Simplex Virus
40%
Genital Herpes
29%
Secretion (Process)
26%
Mucosal Immunity
21%
Mediator
21%
Virus Infection
21%
Herpes Simplex Virus 2
19%
Virus
15%
Blood Plasma
15%
Vaginal Microbicide
14%
Microbiome
14%
Vaginitis
14%
Escherichia coli
14%
Human Immunodeficiency Virus Infection
13%
Vaginal Flora
13%
COVID-19
12%
Human Immunodeficiency Virus 1
12%
Inflammation
11%
Viral Load
10%
Nonoxynol-9
10%
T-Helper Cell
9%
Lactobacillus
9%
Coinfection
9%
Gene Expression
9%
In Vitro
8%
Immunoglobulin A
8%
Wart Virus
8%
Susceptibility
8%
Hepatitis C Virus
8%
Ribonucleic Acid
8%
Bactericidal Activity
7%
Peptides
7%
Antiviral Activity
7%
Chemokine
7%
Seminal Plasma
7%
Cytokine
7%
Antimicrobial Activity
6%
T Cell
6%
Glycoprotein
5%
Tenofovir
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antimicrobial Agent
38%
Wart Virus
27%
Herpes Simplex Virus
23%
Secretion (Process)
19%
Precancerous Condition
19%
COVID-19
18%
Placebo
16%
Lavage
16%
Infection
15%
Mediator
15%
Herpes Genitalis
14%
Clinical Trial
14%
Carcinogenesis
11%
Sexually Transmitted Disease
11%
Mucosal Immunity
11%
Human Immunodeficiency Virus Infection
11%
Escherichia coli
10%
Bacterial Vaginosis
10%
Herpes Simplex
9%
Virus Infection
9%
Odds Ratio
8%
Cervical Cancer Screening
8%
Diseases
8%
Colposcopy
8%
Virus
8%
Uterine Cervix Cytology
8%
Papanicolaou Stain
8%
Papillomavirus Infection
7%
Squamous Cell
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Pre-Exposure Prophylaxis
6%
Convalescence
6%
Host Resistance
6%
Education
5%
Virus Attachment
5%
Antiviral Activity
5%